Highlights from the 12th World Conference on Lung Cancer - CME
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA; David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN; David Jackman, MD, Dana-Farber Cancer Institute, Boston, MD.

12th World Conference on Lung Cancer: Updates in the Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) - CME
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA

12th World Conference on Lung Cancer: Advances in the Management of Advanced NSCLC: Are We Making Progress? - CME
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN

12th World Conference on Lung Cancer: Malignant Pleural Mesothelioma Updates - CME
David Jackman, MD, Dana-Farber Cancer Institute, Boston, MA

12th World Conference on Lung Cancer: Advances in the Management of Small-Cell Lung Cancer (SCLC) - CME
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN

Avastin® Not Contraindicated in Patients with CNS Metastases (3/8/2010)
Researchers from France have reported that patients with central nervous system (CNS) metastases have similar rates of whether or not they receive Avastin® (bevacizumab). The details of this study appeared in the January 2010 issue of Clinical Cancer Research.

Surgery Maybe Effective in Selected Patients with Limited-stage SCLC (2/17/2010)
Researchers from the State University of New York Downstate Medical Center have reported that the use of surgery, especially lobectomy, in patients with limited-stage small cell lung cancer (SCLC) is associated with improved survival outcomes. The details of this study were published early online in Cancer on January 15, 2010.

Smoking Cessation Benefits Patients with Early-stage Lung Cancer (2/12/2010)
Researchers from the UK have reported that smoking cessation after the diagnosis of early stage non–small cell lung cancer (NSCLC) or limited stage small cell lung cancer (SCLC) improves survival. The details of this study were published in the January 30, 2010 issue of the British Medical Journal.

Iressa® Superior to Platinol® and Taxotere® for Treatment of NSCLC with EGFR Mutations (2/5/2010)
Researchers from Japan have reported that Iressa® (gefitinib) alone improves progression-free survival (PFS) of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR) mutations compared with patients receiving Platinol® (cisplatin) plus Taxotere® (docetaxel). The details of this study were published in the February 2010 issue of Lancet Oncology.

Figitumumab Active in Lung Cancer, Adrenocortical Carcinoma, Ovarian Cancer, and Ewing’s Sarcoma (1/11/2010)
Recent Phase I and II studies have suggested that figitumumab, a monoclonal antibody that targets insulin-like growth factor-1 receptor, is active for the treatment of several cancers.